In translation, all BCL2-negative malignancies (e.g., Burkitt lymphoma, BCL2-negative DLBCL, or a substantial part of MM) are inherently “resistant” to BCL2 inhibition with venetoclax but still may be effectively targeted with other BH3 mimetics, e.g., MCL1 inhibitors. This evidence concerns the gene BCL2 and Miyoshi myopathy.